N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Radioactive drugs, such as iodine I 131 metaiodobenzylguanidine (MIBG), may carry
radiation directly to tumor cells and not harm normal cells. A bone marrow or peripheral stem
cell transplant using stem cells from the patient may be able to replace blood-forming cells
that were destroyed by I 131 MIBG.
PURPOSE: This phase II trial is studying the side effects and best dose of iodine I 131 MIBG
followed by a stem cell transplant in treating young patients with relapsed or refractory
high-risk neuroblastoma.